Findings expand Telomir-1’s oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL / ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback